This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
The CLL Society has quickly and organically become one of the leading charities serving the CLL community and takes this responsibility seriously. As part of the Steering Committee of the CLL Advocates Network (CLLAN), Dr. Koffman helps guide other nonprofits, large and small, from around the world in their mission to help CLL patients in their local countries. Please read CLLAN’s inaugural Newsletter here.
The CLL Society 2020 Patient Survey: MRD Testing & Limited Duration Therapy
Help the CLL Society find out what our CLL patients and their caregivers know and still “yearn to learn” about MRD testing (for Minimal Residual Disease) and Limited Duration Therapies. Your input + our future programming = Smarter Patients Getting Smarter Care! Please complete our 2020 Patient Survey. Thank you!
CLL Society Global Virtual Patient & Caregiver Educational Forum October 10!
The BIG event! CLL Society’s first-ever Virtual Global Patient Educational Forum. Register now! Can’t miss topics from CLL experts, including early management in CLL, Test Before Treat, frontline therapy options, 2nd-line and later therapies, measuring response, MRD, COVID-19, clinical trials, CAR-T, vaccines, Richter’s Transformation, and more! Hear from patients and caregivers about being your own advocate and learn the value of joining support groups.
ASH 2019 Drs. Brian Koffman and Richard Furman discuss the effectiveness and tolerability of covalent irreversible BTK inhibitors such as acalabrutinib, ibrutinib, and zanubrutinib, as well as non-covalent, reversible (3rd generation) BTK inhibitors such as vecabrutinib, LOXO 305, and ArQule 561.
Archived Webinar from Cancer Coach Live “What You Need to Know about BTK Inhibitors as Treatment for Your/Your Loved One’s CLL”
Now available on-demand, the August 10 Cancer Coach Live webinar, featuring CLL expert Dr. Matthew Davids, Associate Professor of Medicine Harvard Medical School, Nurse Practitioner Josie Montegaard, and CLL patient, frequent patient panelist, and CLL Society Tribune contributor, Doreen Zetterlund, promoting meaningful and productive dialog between patients and HCPs as relates to CLL treatment regimens incorporating BTK inhibitors. Watch the recorded webinar here.
Please Support the CLL Society, the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
Thank you and stay safe!
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.